References
- Marble A. Insulin in the treatment of diabetes. In: Marble A, Krall LR Bradley RF, et al, eds. Joslin's diabetes mellitus. 12th ed. Philadelphia: Lea & Febiger, 1985: 380–405
- Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979: 2(3): 283–95
- Lebovitz HE, Feinglos MN. Therapy of insulin-independent diabetes mellitus: general considerations. Metabolism 1980: 29(5): 474–81
- Galloway JA. Insulin treatment for the early 80s: facts and questions about old and new insulins and their usage. Diabetes Care 1980: 3(5): 615–22
- Skyler JS. A plethora of insulins. (Editorial) Diabetes Care 1980: 3(5): 638–9
- Fineberg SE, Galloway JA, Fineberg NS, et al. Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Diabetes 1983: 32(7): 592–9
- Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981: 4(3): 366–76
- Gulan M, Gottesman IS, Zinman B. Biosynthetic human insulin improves postprandial glucose excursions in type I diabetes. Ann Intern Med 1987: 107(4): 506–9
- Schade DS, Santiago JV, Skyler JS, et al. Intensive insulin therapy. New York: Elsevier Science Publishing (Excerpta Medica), 1983
- Selam JL, Charles MA. Devices for insulin administration. Diabetes Care 1990: 13(9): 955–79
- Turner RC, Holman RR. Insulin use in NIDDM: rationale based on pathophysiology of disease. Diabetes Care 1990: 13(9): 1011–20
- Spangler RS. Insulin administration via liposomes. Diabetes Care 1990: 13(9): 911–22
- Brange J, Owens DR, Kang S. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990: 13(9): 923–54
- Rifkin H, ed. The physicians guide to type II diabetes (NIDDM): diagnosis and treatment. Alexandria, VA; American Diabetes Assn, 1984
- Sperling MA, ed. Physician's guide to insulin-dependent (type I) diabetes: diagnosis and treatment. Alexandria, VA: American Diabetes Assn, 1988
- Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 1989: 12(9): 641–8
- Genuth S. Insulin use in NIDDM. Diabetes Care 1990: 13(12): 1240–64
- Galloway JA. Treatment of NIDDM with insulin agonists or substitutes. Diabetes Care 1990: 13(12): 1209–39
- Beaser RS, Hare JW. Treatment of the patient with type I diabetes. In: Messerli FH, Riddick FA Jr, Dalessio DJ, et al, eds. Current clinical practice. Philadelphia: WB Saunders, 1987: 539–42
- Hirsch IB, Farkas-Hirsch R, Skyler JS. Intensive insulin therapy for treatment of type I diabetes. Diabetes Care 1990: 13(12): 1265–83
- DCCT Research Group. Diabetes Control and Complications Trial (DCCT): update. Diabetes Care 1990: 13(4): 427–33
- Bolli GB, De Feo P, De Cosmo S, et al. Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 1984: 33(12): 1150–3